Halozyme Therapeutics/$HALO
Halozyme shares fall after its modest FY26 guidance increase barely topped consensus, disappointing investors despite Q3 earnings and revenue beats and prompting a sell-the-news reaction after a strong run.
6 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Ticker
- $HALO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- San Diego, United States
- Website
- halozyme.com
HALO Metrics
BasicAdvanced
$14B
36.36
$3.38
0.88
-
Price and volume
Market cap
$14B
Beta
0.88
52-week high
$134.00
52-week low
$61.23
Average daily volume
2.2M
Financial strength
Current ratio
2.709
Quick ratio
1.994
Long term debt to equity
13.721
Total debt to equity
15.177
Interest coverage (TTM)
46.52%
Profitability
EBITDA (TTM)
1,050.688
Gross margin (TTM)
76.27%
Net profit margin (TTM)
24.86%
Operating margin (TTM)
56.77%
Effective tax rate (TTM)
29.10%
Revenue per employee (TTM)
$3,930,000
Management effectiveness
Return on assets (TTM)
25.49%
Return on equity (TTM)
173.67%
Valuation
Price to earnings (TTM)
36.356
Price to revenue (TTM)
8.688
Price to book
97.69
Price to tangible book (TTM)
-10.31
Price to free cash flow (TTM)
27.881
Free cash flow yield (TTM)
3.59%
Free cash flow per share (TTM)
4.41
Growth
Revenue change (TTM)
41.15%
Earnings per share change (TTM)
-22.52%
3-year revenue growth (CAGR)
29.08%
10-year revenue growth (CAGR)
27.30%
3-year earnings per share growth (CAGR)
25.71%
10-year earnings per share growth (CAGR)
20.52%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Analyst projections of the future price of Halozyme Therapeutics stock.
Bulls say / Bears say
Third-quarter revenue rose 39% year on year and royalties rose 44%; Halozyme also lifted its 2026 revenue and earnings guidance. This points to strong near-term growth in its royalty engine. (PR Newswire)
The FDA approved J&J’s RYBREVANT FASPRO for a new head and neck cancer use, adding another approved ENHANZE-enabled product to Halozyme’s royalty opportunity. (PR Newswire)
Halozyme signed five new ENHANZE and Hypercon collaboration agreements by July 2026, ahead of its full-year goal of three. These deals broaden the pool of potential future milestone and royalty streams, although they still need to produce successful products. (Halozyme Therapeutics, Inc.)
Royalties remain concentrated in a few partner drugs: DARZALEX generated $153.5 million and VYVGART $88.1 million of Halozyme’s $341 million in third-quarter royalties. Weaker sales or slower uptake of either product could weigh materially on growth. (The Motley Fool)
Some ENHANZE royalty rates are expected to step down as key patents expire; management has identified 2029 step-downs for DARZALEX SC and VYVGART Hytrulo in certain markets. That could temper growth even if partner-product sales keep rising. (Investing.com)
At the end of September, Halozyme had $3.3 billion of long-term debt against $1.08 billion of cash and marketable securities, after issuing $1.5 billion of convertible notes. This sizable debt and convertible balance adds financing and potential dilution risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
Upcoming events
No upcoming events
HALO News
AllArticlesVideos
Funds containing HALO
AllUSDEURGBP
Fund name | Fund size | $HALO weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.46% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.46% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.46% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.92% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.92% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.